13 Avenue Morane Saulnier
Vélizy-Villacoublay 78140
France
33 1 39 46 51 04
https://www.novacyt.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 120
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. James Martin McCarthy | Acting CEO & Director | 411,63k | S.O. | 1966 |
Mr. Steve Gibson | CFO & Director | S.O. | S.O. | S.O. |
Bryan Close | Chief Operations Officer | S.O. | S.O. | S.O. |
Ms. Mandy Cowling | Corporate & Investor Relations Manager | S.O. | S.O. | S.O. |
Mr. David Franks | Chief Human Resources Officer | S.O. | S.O. | S.O. |
Paul Oladimeji | Group Head of R&D | S.O. | S.O. | S.O. |
Mr. Lyn Dafydd Rees | Executive Director | S.O. | S.O. | 1973 |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
L’ISS Governance QualityScore de Novacyt S.A. en date du 1 avril 2024 est 4. Les scores principaux sont Audit : 10; Société : 5; Droits des actionnaires : 7; Compensation : 4.